Agilent Technologies, Inc. (A) vs Alnylam Pharmaceuticals, Inc. (ALNY)
A leads on 8 of 14 compared metrics.
A side-by-side comparison of Agilent Technologies, Inc. and Alnylam Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 14, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
A
Agilent Technologies, Inc.
$135.93HealthcareDelayed quote: Jul 15, 2026, 10:45 AM EDT
ALNY
Alnylam Pharmaceuticals, Inc.
$282.80HealthcareDelayed quote: Jul 15, 2026, 10:45 AM EDT
Total return — A vs ALNY
growth of $100 · dividends reinvested · last 22yA +809.6%ALNY +4579.9%ALNY compounded faster
Log scale — wide-divergence pair
A ALNY
A vs ALNY: by the numbers
- •A is the larger company ($38.39B vs $37.76B market cap).
- •A trades at the lower earnings multiple (27.15 vs 66.81 P/E).
- •A converts more revenue to profit (19.55% vs 13.46% net margin).
- •ALNY grew revenue faster over the past five years (49.67% vs 4.45% CAGR).
- •A pays a dividend (0.74% yield) while ALNY does not currently pay one.
Which is better, A or ALNY?
Metric tally: A 8 · ALNY 6It depends on what you're optimizing for:
ValueA(lower P/E)
GrowthALNY(faster 5Y revenue CAGR)
QualityALNY(higher ROIC)
Metrics side by side
Valuation
| Metric | A | ALNY |
|---|---|---|
| P/E ratio | 27.15● | 66.81 |
| Forward P/E | 22.32● | 37.91 |
| P/S ratio | 5.31● | 9.07 |
| P/B ratio | 5.39● | 36.15 |
| PEG ratio | 9.44 | — |
| EV / EBITDA | 21.80● | 47.64 |
| FCF yield | 3.27%● | 1.65% |
Profitability
| Metric | A | ALNY |
|---|---|---|
| Gross margin | 53.00% | 80.89%● |
| Operating margin | 21.50%● | 17.54% |
| Net margin | 19.55%● | 13.46% |
| ROE | 19.85% | 53.68%● |
| ROIC | 12.57% | 13.74%● |
Dividends
| Metric | A | ALNY |
|---|---|---|
| Dividend yield | 0.74% | — |
| Payout ratio | 21.92% | — |
Growth (annualized)
| Metric | A | ALNY |
|---|---|---|
| Revenue CAGR (5Y) | 4.45% | 49.67%● |
| EPS CAGR (5Y) | 14.52% | — |
| FCF CAGR (5Y) | 0.05% | 14.35%● |
| Total return CAGR (5Y) | -1.18% | 10.55%● |
Frequently asked
- Which is better, A or ALNY?
- It depends on your goal. value: A (lower P/E); growth: ALNY (faster 5Y revenue CAGR); quality: ALNY (higher ROIC). Across all compared metrics, A leads 8 to 6.
- Is A or ALNY cheaper?
- On trailing earnings, A is cheaper: A trades at a 27.15 P/E and ALNY at 66.81.
- Which has grown faster, A or ALNY?
- Over the past five years, ALNY grew revenue faster — A at a 4.45% CAGR versus ALNY at 49.67%.
- Does A or ALNY pay a bigger dividend?
- A pays a dividend (0.74% yield) while ALNY does not currently pay one.
- Is A or ALNY more profitable?
- A runs the higher net margin — A at 19.55% versus ALNY at 13.46%.
- Which has been the better investment, A or ALNY?
- Over the past 10-year, ALNY delivered the higher annualized total return — A at 12.06% versus ALNY at 16.14%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Agilent Technologies P/E ratioAlnylam Pharmaceuticals P/E ratioAgilent Technologies dividend yieldAlnylam Pharmaceuticals dividend yieldAgilent Technologies ROEAlnylam Pharmaceuticals ROEAgilent Technologies operating marginAlnylam Pharmaceuticals operating marginAgilent Technologies revenue growthAlnylam Pharmaceuticals revenue growthAgilent Technologies free cash flowAlnylam Pharmaceuticals free cash flow
Agilent Technologies & Alnylam Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 14, 2026.